SG11201407220YA - N-alkyltriazole compounds as lpar antagonists - Google Patents
N-alkyltriazole compounds as lpar antagonistsInfo
- Publication number
- SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- new jersey
- compounds
- drive
- designated states
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 December 2013 (27.12.2013) WIPOIPCT (10) International Publication Number WO 2013/189864 A1 (51) International Patent Classification: C07D 249/06 (2006.01) A61P 29/00 (2006.01) A61K 31/4192 (2006.01) A61P 37/00 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/062461 17 June 2013 (17.06.2013) English English (30) Priority Data: 61/661,961 20 June 2012 (20.06.2012) US (71) Applicant (for all designated States except KM, US): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacher- strasse 124, CH-4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; 340 Kingsland Street, Nutley, New Jersey 07110 (US). (72) Inventors: GABRIEL, Stephen Deems; 49 North Star Drive, Morristown, New Jersey 07960 (US). HAMILTON, Matthew Michael; 24 Mockingbird Road, Hackettstown, New Jersey 07840 (US). LUCAS, Matthew C.; 5132 Lexington Ridge Drive, #5132, Lexington, Mas sachusetts 02421 (US). QIAN, Yimin; 81 Agawam Drive, Wayne, New Jersey 07470 (US). SIDDURI, Achy- utharao; 10 Haggerty Drive, West Orange, New Jersey 07052 (US). (74) Agent: HEIROTH, Ulrike; Grenzacherstrasse 124, CH- 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(ivf) Published: — with international search report (Art. 21(3)) (54) Title: N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS 00 o\ 00 (I) i-H (57) Abstract: Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the © substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are CJ useful for the treatment of inflammatory diseases and disorders such as, for example, pulmonary fibrosis...
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661961P | 2012-06-20 | 2012-06-20 | |
| PCT/EP2013/062461 WO2013189864A1 (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407220YA true SG11201407220YA (en) | 2014-12-30 |
Family
ID=48628667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407220YA SG11201407220YA (en) | 2012-06-20 | 2013-06-17 | N-alkyltriazole compounds as lpar antagonists |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US9321738B2 (en) |
| EP (1) | EP2864300A1 (en) |
| JP (1) | JP2015520202A (en) |
| KR (1) | KR20150021057A (en) |
| CN (1) | CN104411692A (en) |
| AU (1) | AU2013279512A1 (en) |
| BR (1) | BR112014030685A2 (en) |
| CA (1) | CA2869541A1 (en) |
| CL (1) | CL2014003243A1 (en) |
| CO (1) | CO7131358A2 (en) |
| CR (1) | CR20140525A (en) |
| EA (1) | EA201492285A1 (en) |
| HK (1) | HK1206342A1 (en) |
| IL (1) | IL236088A0 (en) |
| IN (1) | IN2014DN09348A (en) |
| MA (1) | MA37764A1 (en) |
| MX (1) | MX2014014710A (en) |
| PE (1) | PE20142448A1 (en) |
| PH (1) | PH12014502789A1 (en) |
| SG (1) | SG11201407220YA (en) |
| UA (1) | UA109868C2 (en) |
| WO (1) | WO2013189864A1 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014003499A2 (en) | 2011-08-15 | 2017-06-13 | Intermune Inc | pharmaceutically acceptable compounds or salts thereof and pharmaceutical compositions and their uses of effective amounts and methods for treating, preventing, reversing, stopping or retarding the progression of selected disease or condition of fibrosis, cancer or respiratory disorders and modulating receptor activity in cells |
| CA2869564A1 (en) * | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-aryltriazole compounds as lpar antagonists |
| DK2988743T3 (en) | 2013-03-15 | 2021-03-01 | Epigen Biosciences Inc | HETEROCYCLIC COMPOUNDS WHICH MAY BE USED FOR DISEASE TREATMENT |
| CA2953472C (en) | 2014-06-27 | 2022-08-02 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
| AR108838A1 (en) * | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | CARBAMOYLOXIMETHYL ACID TRIAZOL CYCLOHEXILO AS LPA ANTAGONISTS |
| JP7299892B2 (en) | 2017-12-19 | 2023-06-28 | ブリストル－マイヤーズ スクイブ カンパニー | Pyrazolazine cyclohexylate as an LPA antagonist |
| MX2020005874A (en) | 2017-12-19 | 2020-08-13 | Bristol Myers Squibb Co | Pyrazole n-linked carbamoyl cyclohexyl acids as lpa antagonists. |
| SG11202005698XA (en) * | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Cyclohexyl acid triazole azines as lpa antagonists |
| EP3728224B1 (en) * | 2017-12-19 | 2023-01-11 | Bristol-Myers Squibb Company | Cyclohexyl acid triazole azoles as lpa antagonists |
| ES2925626T3 (en) * | 2017-12-19 | 2022-10-19 | Bristol Myers Squibb Co | Isoxazole-O-carbamoylcyclohexyl acids as LPA antagonists |
| SI3710438T1 (en) * | 2017-12-19 | 2022-01-31 | Bristol-Myers Squibb Company | Triazole n-linked carbamoyl cyclohexyl acids as lpa antagonists |
| ES2943661T3 (en) | 2017-12-19 | 2023-06-15 | Bristol Myers Squibb Co | Pyrazole-O-linked cyclohexylic carbamoyl acids as LPA antagonists |
| KR20200100754A (en) | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Cyclohexyl acid isoxazole azole as an LPA antagonist |
| KR20200100722A (en) * | 2017-12-19 | 2020-08-26 | 브리스톨-마이어스 스큅 컴퍼니 | Cyclohexyl acid isoxazole azine as an LPA antagonist |
| CN112041304A (en) | 2017-12-19 | 2020-12-04 | 百时美施贵宝公司 | Isoxazole N-linked carbamoylcyclohexanoic acids as LPA antagonists |
| ES2924704T3 (en) | 2017-12-19 | 2022-10-10 | Bristol Myers Squibb Co | Pyrazole azoles of cyclohexyl acid as LPA antagonists |
| CN117126152A (en) * | 2017-12-29 | 2023-11-28 | 生物马林药物股份有限公司 | Glycolate oxidase inhibitors for use in the treatment of disease |
| JP7412424B2 (en) * | 2018-09-18 | 2024-01-12 | ブリストル－マイヤーズ スクイブ カンパニー | Oxabicycloic acid as an LPA antagonist |
| KR20210060547A (en) * | 2018-09-18 | 2021-05-26 | 브리스톨-마이어스 스큅 컴퍼니 | Cycloheptyl acid as an LPA antagonist |
| WO2020060915A1 (en) * | 2018-09-18 | 2020-03-26 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
| CA3158743A1 (en) * | 2019-11-15 | 2021-05-20 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| CN115867556A (en) | 2020-06-03 | 2023-03-28 | 吉利德科学公司 | LPA receptor antagonists and uses thereof |
| TWI838626B (en) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa receptor antagonists and uses thereof |
| CN117295717A (en) | 2021-05-11 | 2023-12-26 | 吉利德科学公司 | LPA receptor antagonists and uses thereof |
| US11939318B2 (en) | 2021-12-08 | 2024-03-26 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| AR128613A1 (en) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH THE ACTIVITY OF THE LPA RECEPTOR |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200827346A (en) | 2006-11-03 | 2008-07-01 | Astrazeneca Ab | Chemical compounds |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| US20110065695A1 (en) | 2009-09-11 | 2011-03-17 | Jeremy Beauchamp | Use of aminodihydrothiazines for the treatment or prevention of diabetes |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| WO2011159550A2 (en) * | 2010-06-14 | 2011-12-22 | Amidra Pharmaceuticals, Inc. | Lysophosphatidic acid receptor antagonist and uses thereof |
| WO2011159633A1 (en) | 2010-06-15 | 2011-12-22 | Amira Pharmaceuticals, Inc. | Inhalable formulations of lysophosphatdic acid receptor antagonists |
| JP2014508111A (en) | 2010-12-07 | 2014-04-03 | アミラ ファーマシューティカルス，インコーポレーテッド | Lysophosphatidic acid receptor antagonist, its use in the treatment of fibrosis |
| WO2012138648A1 (en) | 2011-04-06 | 2012-10-11 | Irm Llc | Compositions and methods for modulating lpa receptors |
| BR112014003499A2 (en) * | 2011-08-15 | 2017-06-13 | Intermune Inc | pharmaceutically acceptable compounds or salts thereof and pharmaceutical compositions and their uses of effective amounts and methods for treating, preventing, reversing, stopping or retarding the progression of selected disease or condition of fibrosis, cancer or respiratory disorders and modulating receptor activity in cells |
-
2013
- 2013-06-17 SG SG11201407220YA patent/SG11201407220YA/en unknown
- 2013-06-17 MX MX2014014710A patent/MX2014014710A/en unknown
- 2013-06-17 PE PE2014002232A patent/PE20142448A1/en not_active Application Discontinuation
- 2013-06-17 WO PCT/EP2013/062461 patent/WO2013189864A1/en active Application Filing
- 2013-06-17 EP EP13729330.4A patent/EP2864300A1/en not_active Withdrawn
- 2013-06-17 IN IN9348DEN2014 patent/IN2014DN09348A/en unknown
- 2013-06-17 CA CA2869541A patent/CA2869541A1/en not_active Abandoned
- 2013-06-17 MA MA37764A patent/MA37764A1/en unknown
- 2013-06-17 EA EA201492285A patent/EA201492285A1/en unknown
- 2013-06-17 UA UAA201500428A patent/UA109868C2/en unknown
- 2013-06-17 JP JP2015517704A patent/JP2015520202A/en not_active Ceased
- 2013-06-17 US US14/401,009 patent/US9321738B2/en not_active Expired - Fee Related
- 2013-06-17 CN CN201380032285.0A patent/CN104411692A/en active Pending
- 2013-06-17 KR KR1020147035768A patent/KR20150021057A/en not_active Application Discontinuation
- 2013-06-17 BR BR112014030685A patent/BR112014030685A2/en not_active Application Discontinuation
- 2013-06-17 AU AU2013279512A patent/AU2013279512A1/en not_active Abandoned
-
2014
- 2014-11-17 CR CR20140525A patent/CR20140525A/en unknown
- 2014-11-21 CO CO14256136A patent/CO7131358A2/en unknown
- 2014-11-28 CL CL2014003243A patent/CL2014003243A1/en unknown
- 2014-12-04 IL IL236088A patent/IL236088A0/en unknown
- 2014-12-15 PH PH12014502789A patent/PH12014502789A1/en unknown
-
2015
- 2015-07-21 HK HK15106927.8A patent/HK1206342A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9321738B2 (en) | 2016-04-26 |
| JP2015520202A (en) | 2015-07-16 |
| IL236088A0 (en) | 2015-02-01 |
| MX2014014710A (en) | 2015-03-04 |
| WO2013189864A1 (en) | 2013-12-27 |
| MA37764A1 (en) | 2016-01-29 |
| CO7131358A2 (en) | 2014-12-01 |
| CN104411692A (en) | 2015-03-11 |
| BR112014030685A2 (en) | 2017-06-27 |
| CA2869541A1 (en) | 2013-12-27 |
| CR20140525A (en) | 2015-01-12 |
| PE20142448A1 (en) | 2015-01-28 |
| EA201492285A1 (en) | 2015-04-30 |
| CL2014003243A1 (en) | 2015-03-20 |
| KR20150021057A (en) | 2015-02-27 |
| AU2013279512A1 (en) | 2014-10-16 |
| PH12014502789A1 (en) | 2015-02-09 |
| US20150133511A1 (en) | 2015-05-14 |
| UA109868C2 (en) | 2015-10-12 |
| EP2864300A1 (en) | 2015-04-29 |
| IN2014DN09348A (en) | 2015-07-17 |
| HK1206342A1 (en) | 2016-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201407229UA (en) | Substituted pyrazole compounds as lpar antagonists | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201908560SA (en) | Heterocyclic compounds useful as dual atx/ca inhibitors | |
| SG11201806745RA (en) | Sulfonylureas and related compounds and use of same | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201804758QA (en) | Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab | |
| SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
| SG11201408318RA (en) | Compositions and methods for transmucosal absorption | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201407337QA (en) | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11201908691PA (en) | Compounds and methods for the treatment of parasitic diseases | |
| SG11201806424TA (en) | Therapeutic compounds |